#China #Suzhou #Innovent Biologics #Mazdutide #PECONDLE

Innovent Biologics Introduces Seven Groundbreaking Products for 2026 National Reimbursement Drug List

In a remarkable advancement for patients and the healthcare landscape, Innovent Biologics, Inc., a leader in biopharmaceutical innovation, announced that seven of its pioneering products have successfully gained entry into the updated National Reimbursement Drug List (NRDL) for 2026. This pivotal inclusion is expected to significantly enhance accessibility and affordability of vital treatments for numerous patients across various disease areas, including oncology, metabolic disorders, and autoimmune diseases.

Key Products Included in the NRDL

The newly included products span a spectrum of therapeutic areas:
1. Mazdutide - A GCG/GLP-1 dual receptor agonist.
2. PECONDLE® (picankibart injection) - An IL-23p19 inhibitor.
3. TABOSUN® (Ipilimumab N01 injection) - A CTLA-4 inhibitor.
4. Vanflyta® (quizartinib) - A Type II FLT3 inhibitor.
5. TYVYT® (sintilimab injection) - An anti-PD-1 monoclonal antibody with new indications.
6. Jaypirca® (pirtobrutinib) - A non-covalent BTK inhibitor with newly added indications.
7. SINTBILO® (tafolecimab injection) - A fully human PCSK9 monoclonal antibody with a successful renewal.

Commitment to Patient Health

Dr. Michael Yu, Founder and CEO of Innovent, expressed his satisfaction with the inclusion of these innovative drugs, emphasizing the company's dedication to addressing significant health concerns. He noted that the new additions cover critical areas such as colonic and renal cancers and various metabolic conditions, which burden the society heavily. With the expanded NRDL coverage, it is anticipated that over 20 million patients will benefit from these advanced treatments, thus reinforcing the medication safety net provided to patients.

"Empowering patients with affordable, high-quality biopharmaceuticals is at our core," Dr. Yu stated. He reiterated the company's alignment with the Healthy China 2030 initiative, amplifying access to quality health solutions.

Highlights of the Newly Included Drugs

- Mazdutide is particularly notable, as it is the world's first and only approved GCG/GLP-1 dual receptor agonist. Clinical studies indicate its effectiveness in lowering blood glucose, promoting insulin secretion, and aiding in weight management, addressing type 2 diabetes in adults with no prior therapeutic options available.
- PECONDLE® targets moderate to severe plaque psoriasis, offering a significant step in systemic therapy options for patients. Its unique formulation allows for better adherence due to its extended maintenance dosing schedule.
- TABOSUN®, in conjunction with sintilimab, presents a novel neoadjuvant treatment option for high-risk colon cancer patients, combining immunotherapy strategies for better outcomes.
- Vanflyta® fills a crucial gap in acute myeloid leukemia treatment, enhancing options for patients with specific genetic markers, thus tailoring therapy to individual needs.
- TYVYT® has seen success in multiple indications now recognized by the NRDL, including its role in advanced kidney cancer therapy.
- Jaypirca® broadens its reach by now including patients with chronic lymphocytic leukemia who have undergone prior therapies.
- SINTBILO® renewal consolidates its status as an essential lipid-lowering option for patients suffering from high cholesterol.

Looking Forward

With the objectives set by China's 15th Five-Year Plan, Innovent remains resolutely focused on innovation. The company is committed to responding to the unmet clinical needs and aims to advance the Research and Development (R&D), manufacturing, and commercialization of innovative drugs that positively impact public health. As Innovent promotes its expanded product lineup and strengthens its partnerships within the industry, it sets an example for future advances in biopharmaceuticals, working towards a healthier populace and a robust pharmaceutical infrastructure in China and beyond.

For further information, visit Innovent Biologics.